0001209191-19-002964.txt : 20190108
0001209191-19-002964.hdr.sgml : 20190108
20190108212812
ACCESSION NUMBER: 0001209191-19-002964
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190104
FILED AS OF DATE: 20190108
DATE AS OF CHANGE: 20190108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mates Sharon
CENTRAL INDEX KEY: 0001585699
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36274
FILM NUMBER: 19517199
MAIL ADDRESS:
STREET 1: C/O INTRA-CELLULAR THERAPIES, INC.
STREET 2: 3960 BROADWAY
CITY: NEW YORK
STATE: NY
ZIP: 10032
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc.
CENTRAL INDEX KEY: 0001567514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 364742850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 212-923-3344
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
FORMER COMPANY:
FORMER CONFORMED NAME: Oneida Resources Corp.
DATE OF NAME CHANGE: 20130122
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-04
0
0001567514
Intra-Cellular Therapies, Inc.
ITCI
0001585699
Mates Sharon
C/O INTRA-CELLULAR THERAPIES, INC.
430 EAST 29TH STREET
NEW YORK
NY
10016
1
1
0
0
Chairman, President & CEO
Common Stock
2019-01-04
4
M
0
6604
A
1190909
D
Common Stock
2019-01-04
4
S
0
38059
11.38
D
1152850
D
Common Stock
2019-01-04
4
S
0
7539
11.82
D
1145311
D
Common Stock
2019-01-07
4
S
0
6604
12.43
D
1138707
D
Restricted Stock Units
2019-01-04
4
M
0
6604
0.00
D
Common Stock
6604
0
D
Stock Option (right to buy)
12.73
2019-01-08
4
A
0
172697
0.00
A
2029-01-07
Common Stock
172697
172697
D
Restricted Stock Units
2019-01-08
4
A
0
125687
0.00
A
Common Stock
125687
125687
D
Restricted stock units convert into common stock on a one-for-one basis.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2018. A majority of the proceeds from these sales will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.78 to $11.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.79 to $11.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.07 to $12.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Each restricted stock unit represents a contingent right to receive one share of common stock.
On January 4, 2016, the reporting person was granted 19,811 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
On January 8, 2019, the reporting person was granted options to purchase 172,697 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
On January 8, 2019, the reporting person was granted 125,687 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
/s/ Lawrence J. Hineline, Attorney-in-fact
2019-01-08